ArticleScientific reports2025
Prediction of the 180 day functional outcomes in aneurysmal subarachnoid hemorrhage using an optimized XGBoost model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic Value of Admission D-dimer Levels and Total Bleeding Volume in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Cohort Study with Machine Learning-Based Modeling.Neurocritical care · 2026Article
- Machine Learning-Based Prediction of Delayed Cerebral Ischemia and Functional Outcome in Aneurysmal Subarachnoid Hemorrhage: The Role of CNS Infection-Related Parameters.Biomedicines · 2026Article
- Non-contrast computed tomography at the end of the acute care phase as an additional prognostic tool after aneurysmal subarachnoid hemorrhage.Neurosurgical review · 2026Article
- Inflammation, coagulation, and nutritional reserves refine 90-day prognostic stratification after ruptured intracranial aneurysm repair.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Conventional models are unable to fully assess the complexity of aneurysmal subarachnoid hemorrhage (aSAH). In this study, we developed a predictive model using the extreme gradient boosting (XGBoost) algorithm to guide individualized treatment by combining inflammatory markers and clinical grading. The study was retrospectively analyzed using 264 patients with aSAH admitted to Yongchuan Hospital of Chongqing Medical University from January 2020 to December 2022 as a training cohort and 88 patients admitted from January 2023 to December 2023 as an external validation cohort. Patients were categorized into favorable and unfavorable prognosis groups based on 6-month modified Rankin Scale (mRS) scores. Significant predictors identified by multivariate logistic regression included NAR, procalcitonin, CRP, D-dimer, and modified Fisher scores. The model had an AUC of 0.87 and a Brier score of 0.13; the validation cohort had an AUC of 0.85 and a Brier score of 0.18. Decision curve analyses underscored the consistent net benefit of the model across thresholds. This study emphasizes the value of integrating clinical and laboratory markers in prognostic prediction and supports targeted interventions to reduce risk and improve prognosis in patients with aSAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.